Want to see HUMA full AI Analyst Report?
HUMA Stock Chart & Stats
$0.71
-$0.19(-4.01%)
At close: 4:00 PM EST
$0.71
-$0.19(-4.01%)
Day’s Range― - ―
52-Week Range$0.55 - $2.84
Previous CloseN/A
Volume1.64M
Average Volume (3M)8.74M
Market Cap
$191.44M
Enterprise Value$180.14M
Total Cash (Recent Filing)$48.54M
Total Debt (Recent Filing)$65.90M
Price to Earnings (P/E)―
Beta2.96
Next Earnings
Aug 17, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding269,638,150
10 Day Avg. Volume9,930,357
30 Day Avg. Volume8,735,596
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)48.86
Price to Sales (P/S)74.54
P/FCF Ratio-1.43
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue89.35
Enterprise Value/Gross Profit-11.94
Enterprise Value/Ebitda-2.26
Forecast
1Y Price Target
$1.96Price Target Upside175.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.34
Revenue Forecast (FY)$6.51M
Bulls Say, Bears Say
Bulls Say
Phase 3 V012 SuccessMeeting the Phase 3 primary endpoint with an early stop and a planned supplemental BLA is a durable regulatory catalyst. A successful approval for dialysis access would open a large, well‑defined hemodialysis market, strengthen payer engagement, and materially expand commercial addressability and long‑term revenue potential.
Global Rights RegainedReacquiring ex‑U.S. rights gives Humacyte direct control of international commercialization, regulatory strategy and partnership negotiations. This structural shift lets the company capture more long‑term upside, coordinate global launches, and pursue country‑specific agreements that support scalable revenue and strategic flexibility.
Early Commercial Traction & HiresSequential unit and revenue growth alongside senior commercial and surgical hires indicates tangible progress converting clinical assets into real world use. Investing in field teams and surgeon education is a durable capability build that supports sustained adoption, repeat use, and a path to scale if clinical and reimbursement momentum continue.
Bears Say
Large Cash BurnVery high negative operating and free cash flow implies ongoing heavy cash consumption that will require continued external funding. Persistent burn constrains strategic optionality, shortens runway absent material commercial scale or financing, and raises dilution and execution risk over the medium term.
Weak Balance Sheet LeverageDebt materially outweighing equity creates a fragile capital structure. High leverage reduces financial flexibility for manufacturing scale‑up and commercialization, increases refinancing risk if markets tighten, and raises the likelihood that setbacks (trial delays, reimbursement issues) pressure liquidity and increase cost of capital.
Commercial Scale Still MinimalDespite rapid percentage growth, absolute commercial revenue is minimal and adoption inconsistent across hospitals. Durable commercial success requires converting early adopters into routine use, securing IDN contracts and reimbursement. Failure to scale would perpetuate losses and make the company reliant on external funding.
Humacyte News
HUMA FAQ
What was Humacyte’s price range in the past 12 months?
Humacyte lowest stock price was $0.55 and its highest was $2.84 in the past 12 months.
What is Humacyte’s market cap?
Humacyte’s market cap is $191.44M.
When is Humacyte’s upcoming earnings report date?
Humacyte’s upcoming earnings report date is Aug 17, 2026 which is in 40 days.
How were Humacyte’s earnings last quarter?
Humacyte released its earnings results on May 13, 2026. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.116 by $0.026.
Is Humacyte overvalued?
According to Wall Street analysts Humacyte’s price is currently Undervalued.
Does Humacyte pay dividends?
Humacyte does not currently pay dividends.
What is Humacyte’s EPS estimate?
Humacyte’s EPS estimate is -0.1.
How many shares outstanding does Humacyte have?
Humacyte has 269,638,150 shares outstanding.
What happened to Humacyte’s price movement after its last earnings report?
Humacyte reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.116. Following the earnings report the stock price went up 24.176%.
Which hedge fund is a major shareholder of Humacyte?
Currently, no hedge funds are holding shares in HUMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Humacyte Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1.96 (175.82% Upside)
$1.96 (175.82% Upside)
Blogger Sentiment
Bullish
HUMA Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 5.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $59.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.22%
12-Months-Change
Fundamentals
Return on Equity
-2781.56%
Trailing 12-Months
Asset Growth
-31.99%
Trailing 12-Months
Company Description
Humacyte
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs). These investigational HAVs are specifically crafted for universal compatibility, enabling easy implantation into any patient without inducing an immune rejection or an adverse foreign body response. Humacyte is currently building a pipeline of HAVs targeting the substantial market for vascular repair, reconstruction, and replacement. This includes applications such as treating vascular trauma, providing arteriovenous access for hemodialysis, addressing peripheral arterial disease, and facilitating coronary artery bypass grafting. Furthermore, the company is exploring the use of its HAVs for pediatric heart surgeries and for cellular therapeutic delivery, including the transplantation of pancreatic islet cells to manage Type 1 diabetes. Founded in 2004, Humacyte maintains its headquarters in Durham, North Carolina.
HUMA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted tangible commercial momentum (Symvess unit and revenue growth), strengthened commercial leadership, international regulatory progress (Israel MAA accepted), strategic government interest (DoD funding), and important near-term clinical catalysts (V012 interim results due June 11 and CTEV Phase I/II planned H2 2026). These operational and pipeline advances were balanced against financial headwinds in the quarter: a swing to a $17.6M net loss driven largely by reduced noncash other income, a large inventory reserve that inflated COGS, increased R&D spend for CTEV manufacturing, and modest absolute product revenue despite high percentage growth. The company has taken actions (restructuring, senior hires, targeted commercialization) to address uptake and cost structure and reported a cash position of $48.9M. Overall, progress on product, pipeline, and commercialization initiatives combined with cost-saving actions and an upcoming trial readout lead to a cautiously optimistic view of the company’s near-term prospects, tempered by the recent negative impact on profitability and remaining timing uncertainties around regulatory and procurement milestones.View all HUMA earnings summariesHUMA Stock 12 Month Forecast
Average Price Target
$1.96
▲(175.82% Upside)
Technical Analysis
Cartesian Therapeutics
―
Allogene Therapeutics
―
―
Foghorn Therapeutics
―
Kyverna Therapeutics, Inc.
―
Ownership Overview
8.14% Insiders
4.80% Mutual Funds
5.23% Other Institutional Investors
77.46% Public Companies and
Individual Investors